Matthew Foy - Profile and Investment Details

Investor Profile

Matthew Foy is a Venture Capital, Corporate Venture Capital, Private Equity Firm based in London, England, United Kingdom with a diverse investment portfolio that includes companies such as Semprus BioSciences, Pulmocide, SR One Capital Management, Syntaxin, CRISPR Therapeutics, Propeller Health, Constellation Pharmaceuticals, Asceneuron, Bicycle Therapeutics, Thrasos, iPierian, Design Therapeutics, Atopix Therapeutics, Decibel Therapeutics, Puridify, Arcellx, HTG Molecular Diagnostics, Gotham Therapeutics, Dicerna Pharmaceuticals, Tranquis Therapeutics, Morphic Therapeutic, F-star Biotechnology, Pandion Therapeutics, Asceneuron SATurning Point Therapeutics, Palleon Pharmaceuticals, Aileron Therapeutics, Akamis Bio, Translate Bio, Nimbus Therapeutics, HotSpot Therapeutics, ZappRx, Nkarta Therapeutics, Principia Biopharma, Psioxus Therapeutics, Second Genome, Genocea Biosciences, Xap Therapeutics, Alios BioPharma, Tioma Therapeutics, River Vision Development, IlluminOss Medical, MISSION Therapeutics, Bird Rock Bio, Atox Bio, Navitor Pharmaceuticals, Econic Biosciences, Spero Therapeutics, Dren Bio, Gladius Pharmaceuticals, MiroBio, Fore Biotherapeutics, Avhana Health, True North Therapeutics, Effector Therapeutics, PRESS London, Progyny, Applied Genetics Technologies Corporation, VHSquared, Zikani Therapeutics, Progenitor Therapeutics, Pulmocide Limited, . Over time, Matthew Foy has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Matthew Foy is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Life Science, Biotechnology, Health Diagnostics, Medical, Therapeutics, Personal Health, Pharmaceuticals may find it worthwhile to explore potential connections with Matthew Foy, as their portfolio suggests a familiarity and interest in this area.

Understanding Matthew Foy’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.